Jennison Associates
RPRX

Jennison Associates’s Repros Therapeutics Inc. RPRX Stock Holding History

Jennison Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,494,980
Closed -$27.4M – 826
2013
Q4 		$27.4M Buy
1,494,980
+255,732
+21% +$4.83M 0.03% 413
2013
Q3 		$33.2M Sell
1,239,248
-1,043,868
-46% -$22.4M 0.03% 375
2013
Q2 		$42.1M Buy
+2,283,116
New +$40.3M 0.05% 310

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Jennison Associates's RPRX Position: Q1 2014 in Review

Jennison Associates sold out of Repros Therapeutics Inc. (RPRX) in Q1 2014, closing a stake of 1,494,980 shares — an estimated $27.4M sold.

Jennison Associates first reported a position in RPRX in Q2 2013 and held it in 3 quarters. The position peaked at $42.1M in Q2 2013. 80 funds tracked by Wall St. Rank hold RPRX as of Q1 2014.

  • Jennison Associates reported no remaining Repros Therapeutics Inc. position as of Q1 2014 after selling out during the quarter.
  • Jennison Associates sold 1,494,980 Repros Therapeutics Inc. shares in Q1 2014, an estimated $27.4M.
  • Jennison Associates first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 3 quarters.
  • Jennison Associates's Repros Therapeutics Inc. position peaked at $42.1M in Q2 2013.
  • 80 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2014.

Based on Jennison Associates's 13F filing for Q1 2014, filed 7 May 2014.